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Abstract 
Background A small minority of patients present with locally advanced cutaneous Squamous 
Cell Carcinoma (cSCC). The aim of this study was to evaluate the effectiveness of Tumor 
necrosis factor α (TNF) and melphalan based isolated limb perfusion (TM-ILP) as a limb 
saving strategy for locally advanced extremity cSCC. 
Methods A retrospective search from prospectively maintained databases at two tertiary 
referral centers was performed to identify patients treated with TM-ILP for locally advanced 
cSSC of an extremity between 2000 and 2015.  
Results A total of 30 patients treated with TM-ILP for cSCC were identified, with a median 
age of 71 years (36-92) and 50% female. Response could not be evaluated in 3 patients. After 
a median follow up of 25 months, the overall response rate was 81% (n=22), with 16 patients 
having a complete response (CR, 59%). A total of 7 patients developed local recurrence, with 
a median time to recurrence of 9 months (Interquartile Range 7 – 10). Progressive disease was 
observed in 5 patients (19%). Limb salvage rate was 80%. The overall 2-year survival was 
67%. 
Conclusions TM-ILP should be considered as an option in patients with locally advanced 
cSCC in specialized centers, resulting in a high limb salvage rate.  
  
 
Background 
Non-melanoma skin cancer (NMSC) is the most frequent human malignancy
1, 2
 with an 
increasing incidence reaching epidemic proportions among Caucasians in Europe, America 
and Australia.
3-8
 Approximately 80% of all NMSC are basal cell carcinomas (BCC) and  20% 
are cutaneous squamous cell carcinomas (cSCC).
6-9
 
Usually cSCC presents as a localised lesion, for which various treatment strategies are 
available:  wide surgical excision, Mohs surgery, cryosurgery, and radiation therapy.  Margins 
of resection are an important prognostic factor for outcome 
10
 and the primary aim of surgery 
is to remove the tumor in total with adequate margins. However some patients will present 
with locally advanced disease. In such locally advanced cases, a radical resection to achieve 
negative surgical margins may lead to serious loss of limb function, or may even require an 
amputation. 
Regional chemotherapy by hyperthermic isolated limb perfusion was introduced  as a 
therapy to treat advanced extremity malignancies either as a standalone treatment or as a neo 
adjuvant treatment to down size a malignancy and facilitate function preserving surgery.
11, 12
 
Several reports show excellent response rates with tumor necrosis factor α (TNF) and 
melphalan based isolated limb perfusion (TM-ILP) for both melanomas with multiple in 
transit metastases and for locally advanced soft tissue sarcomas.
11, 13-15
 Likewise, large series 
show that TM-ILP is a safe procedure with only a limited local toxicity without severe 
systemic toxicity.
16
 These observations  led to the exploration of ILP for locally advanced 
cSCC of the extremities. This study aims to evaluate the effectiveness of TM-ILP as a limb 
saving strategy for locally advanced cSCCs in the extremities. 
 
  
 
Methods 
Patients 
Between 2000 and 2015, all patients treated with TM-ILP for locally advanced cSCC were 
identified from a prospectively maintained database in one of the two tertiary referral 
hospitals: Erasmus MC - Cancer Institute, Rotterdam, the Netherlands, and Royal Marsden 
Hospital, London, United Kingdom. All patients were considered to be surgically treatable 
only by amputation or function disrupting ablative surgery because the extent of tumor 
affecting the limb. Unresectability of the tumor was based on the following factors: size, 
multifocality, number of recurrences, and tumor location (adherent to bones,  blood vessels or 
nerves). All patients were discussed in a multidisciplinary tumor board. The majority of 
patients had chronic infected fungating tumors, and therefore almost all patients underwent 
TM-ILP with prophylactic systemic antibiotics.  
  
 
Perfusion 
The ILP technique has been described extensively before.
17
 Briefly, After heparinization, the 
surgeon isolated the targeted vessels from the systemic circulation and cannulated the vessels 
with silastic cannulae. The surgical approach for cannulation could either be at the inguinal, 
femoral, axillary, or brachial level depending on the location of the tumor. To prevent leakage 
a pneumatic tourniquet was used to compress collateral vessels. Leakage from the isolated 
circulation to the systemic circulation was measured continuously using technetium labelled 
albumin. A dose of 1 to 3 mg (arm) or 1 to 3 mg (leg) of recombinant TNF was injected as a 
bolus. The dose of melphalan raged between 50 and 80 mg for the perfusion of a leg and 
between 25 and 60 mg for an arm based on volume of the limb or body weight.(16) After the 
perfusion, the limb was washed out.  
Toxicity 
Acute regional toxicity after perfusion was classified according to Wieberdink et al. 
18 
 
Regional toxicity and systemic complications were evaluated during the hospital stay or 
during follow up visits.  
Outcome 
The primary outcome measure was response to TM-ILP. Response was measured by clinical 
examination and scored following World Health Organisation criteria. 
19
 Time to local 
progression, systemic disease and overall survival were defined as time from ILP to the event. 
The secondary outcome measure was limb salvage after TM-ILP. TM-ILP could potentially 
be a curative treatment or a neoadjuvant therapy to downsize a tumor prior to radical function 
preserving resection. Both of these approaches were considered to be limb salvage strategies. 
  
 
Statistical analysis 
In this retrospective review, survival analyses were performed using the Kaplan Meier 
method. Differences between groups were assessed by the Log-rank test, T-tests and Fisher 
exact tests. A p-value of 0.05 was considered significant. Confounders for local progression 
and overall survival (OS) were identified using univariate analysis. Only confounders with a 
p-value below 0.1 were subsequently included in a multivariate Cox regression. Factors 
explored were: age, gender, hospital of treatment, site and size of the tumor (<5cm, or >5cm). 
IBM SPSS statistics 24 was used for the statistical analyses.  
 
Results 
Patients 
A total of 30 patients were treated with TM-ILP of which 15 (50%) were female. Median age 
at time of TM-ILP was 71 (Interquartile Range [IR] 62 - 79). Median follow up was 25 
months (IR 10 - 36). TM-ILP was offered in 18 patients with primary disease (60%), in 10 
patients with local recurrent cSCC (33%), and two patients were known to have systemic 
disease and underwent a palliative ILP (7%).Patient, tumor- and treatment characteristics are 
summarized in table 1.  
Treatment outcome 
Response could be evaluated in 27 patients. In three patients response could not be evaluated 
because of, amputation (n=1), or death (n=2) within 3 months after ILP. 
 The overall response (OR) rate of these 27 patients was 81% (n=22). Sixteen patients had a 
complete response (CR, 59%) and 6 patients had a partial response (PR, 22%). An example of 
a complete response is depicted in figure 1. Five patients (19%) had progressive disease (PD) 
within 3 months after TM-ILP. No differences in tumor size (p=1,000), stage of disease 
  
 
(p=0,248), number of tumors (p=0,246) and tumor location (p=0.263) were found between the 
different response groups (Table 2).  
Surgical intervention 
Of all 30 patients, at least 19 patients were candidates for amputation before ILP. Of these 
patients, 13 patients did not need surgical intervention after ILP (68%), 1 patient needed 
resection (5%) and 5 needed amputations (26%). 
Analysing all 30 patients, 12 patients eventually needed surgical intervention after 
TM-ILP (40%), which consisted of resection of tumor in 5 patients (17%), and amputation in 
6 patients (20%)(fig. 2). One patient (3%) needed surgical intervention but refused.  
Of the 5 patients who underwent a limb conserving resection of residual or remaining 
tumor, two patients underwent resection of residual tumor and the tumor was found to be 
100% necrotic on histopathological analysis. Both of these patients were classified as CR. 
Two patients had PD with already metastatic disease at time of ILP. For these patients ILP 
was done with palliative intent because of intractable pain and/or  uncontrollable wounds, but 
due to progression surgery was unavoidable. One patient had a clinical PR and underwent a 
surgical resection of residual tumor which demonstrated viable tumor on histopathological 
analysis. 
Of the 6 patients who underwent an amputation  after TM-ILP, one patient  had an 
initial CR  but subsequently needed amputation after development of local recurrence. After 
resection of the recurrence this patients suffered from severe wound healing problems and 
amputation was unavoidable. Three patients had an amputation because of PD, and one 
patient had a PR but still needed amputation. Finally, one patient needed amputation due to 
ischemia. The median time between TM-ILP and amputation in these 6 patients was 3 months 
(range 0-9). 
  
 
Local progression 
Of the 27 patients were response could be evaluated, five patients (19%) showed no response 
to TM-ILP and had immediate PD. Of all 30 patients, another 7 patients (23%) developed 
local progressive disease during follow up. The median time to local progression for these 7 
patients was 9 months (IR 7 – 10) (table 3). The local progression free survival (PFS) was 
significantly longer in the CR group, compared to the PR group (Log-rank, p=0.018), 
whereby the median PFS for both groups was not reached. None of the following factors were 
associated with duration of PFS: age (p=0.216), gender (p=0.560), hospital (p=0.187), site 
(p=0.862), and size of the tumor (<5cm, or >5cm, p=0.939). 
Systemic Metastasis  
A total of 3 patients in this cohort had lymph node metastases at time of ILP (10%) and were 
treated with lymph node dissection concurrent with ILP. In addition, 3 more patients (10%) 
developed lymph node metastases in the follow up and were treated with lymph node 
dissection with a median time to lymph node metastases of 4 months (range, 0-9)(table 3). 
Systemic metastases were present in two patients (7%) at time of ILP, while two more 
patients (7%) developed systemic disease during follow up: 3 and 21 months after ILP (table 
3).  
Overall survival 
Eighteen patients were alive at last follow up (60%) with a median follow up for this 
particular group of 30 months (IR 18 - 38). In 14 patients (47%) there was no evidence of 
disease at last follow-up. Twelve patients (40%) died during follow up, of whom 6 (20%) died 
of advanced disease, 2 (7%) of complications after surgery, and 4 (13%) of reasons not related 
to cSCC. Median OS was 54 months (95% CI: 20.4-87.6), with a 2 year survival of 67%. 
Gender (p=0.187), hospital (p=0.748), site of cSCC (p=0.241), and size of the tumor 
(<5cm, or >5cm, p=0.370) did not influence overall survival.  
  
 
Complications 
The vast majority of patients in this series did not experience serious local toxicity. In 25 
patients (83%) Wieberdink I or II was observed and in four patients (13%) Wieberdink III. 
One patient (3%) underwent an amputation 9 days following TM-ILP (Wieberdink V) due to 
ischemia. Leakage to the systemic circulation was minimal in all procedures, in only one case 
a leakage of 5% was noted, while in all other cases leakage was 2% or lower. The thirty-day 
mortality following TM-ILP for advanced cSSC was 0, however, two patients died 66 and 71 
days after perfusion. The first patient was admitted to the Intensive Care Unit with respiratory 
distress after his operation and eventually died of pneumonia and respiratory failure. This 
patient had severe comorbidity, including severe chronic pulmonary obstructive disease and 
pre-existing diabetic complications (renal failure and hypertension). The procedure of the 
second patient was complicated due to a rupture of the brachial artery that was cannulated for 
TM-ILP. The patient was re-operated in an outside hospital and a vascular prosthesis was 
inserted. The patient died two months after TM-ILP of septic complications caused by an 
infected vascular prosthesis. 
Discussion 
This unique multicentre experience of 30 TM-ILPs as treatment for locally advanced cSCC  
and demonstrates that TM-ILP is a valuable limb saving strategy in selected patients who 
would otherwise need an amputation or function disrupting ablative surgery. To our 
knowledge, this is the largest report on the outcome of ILP for locally advanced cSCC. With 
an overall response rate of 81%, a CR rate of 59%, and a limb salvage rate of 80%, this data 
shows that ILP is an effective treatment to obtain local control for locally advanced cutaneous 
squamous skin carcinoma. Almost half of the patients were free of disease at the end of follow 
up (n=14, 47%).  
  
 
Reports in the literature of oncological outcomes for advanced unresectable cSCC 
treated by ILP or other modalities are rare. One small study reports a series of 12 ILPs treated 
at multiple centres for cSCC with comparable results to this study (CR of 67% and 75% limb 
salvage rate).
20
  
Other treatment modalities described for advanced cSCC at any site include 
conventional cytotoxic chemotherapy, newer systemic therapies, radiotherapy, and 
combinations of these modalities.
21-30
  The are a number of small case series of patients with 
advanced cSCC treated with cytotoxic chemotherapy usually involving cisplatin.
22, 24, 25
 Only 
2 studies included more than 10 patients, one reporting a CR in 4 out of 14 patients using a 
Cisplatin, 5-FU and bleomycin regime 
22
, and another reporting a PR rates of 56% and 47% 
using either platinum or taxane based chemotherapies respectively. Immunotherapy is mostly 
described using interferon alpha with or without chemotherapy, with the highest CR of 50% 
when combining Retinoid acid, interferon alpha and Cisplatin.
23-26 
More recently targeted therapies have been uses for advanceds cSCC.
25, 28-30 
Two large 
studies evaluated the effectiveness of cetuximab and panitumumab in locally advanced- and 
metastasized cSCC.
28, 30
 Maubec et al. found a CR of 6%, a PR of 26% and an overall 
survival 8.1 months with cetuximab, with 47% of the patients having locally advanced 
cSCC.
28
 Foote et al. found an OR of 31% with panitumumab, including the 13 patients with 
locally advanced cSCC.
30
 
 
There is very limited data regarding durable responses of radiotherapy as single 
treatment in locally advanced cSCC, however adjuvant radiotherapy can significantly improve 
survival in patients with lymph node metastases.
23 
Although the side effects of the TM-ILPs were low in this cohort, we did observe two 
(7%) in hospital deaths within 3 months after TM-ILP which is rare for ILP treatment. One of 
these patients died of pulmonary complications, while this patient was known to have severe 
  
 
co-morbidity including diabetes and severe COPD. Given the low leakage rate it is unlikely 
that his postoperative respiratory problems were caused or exacerbated by systemic leakage of 
the drugs, although we cannot rule this out completely. The second patient died of a 
complication that was directly attributable to ILP ( sepsis subsequent to an infected arterial 
graft after an rupture of the brachial artery at the site of cannulation). Experience from larger 
series of ILP for  the treatment of  sarcoma and melanoma indicate that the mortality rate 
associated with ILP is less than  1% 
15-17, 31-34
 Of interest, both patients were classified as 
American Society of Anesthesiologists physical status classification system (ASA)-3 patients, 
and both patients were treated in the early stages of this ILP treatment. Both centres are far 
more experienced with the procedure now than 15 years ago, and patient selection is more 
strict when it comes to patients with (severe) co-morbidity.  
 
This study is limited by the relatively small number of patients, and therefore the 
results should be read with caution. Also, outcome could not be assessed in 3 out of 30 
patients potentially leading to a bias in response rates. Nevertheless even with these caveats 
the response rates remain higher than other reported treatments. 
21-30
   
 Of interest, the agents used for ILP are derived from the melanoma ILP protocol. In 
literature, results of ILP are reported combining doxorubicin with TNF-a showing similar 
results. 
35, 36
 These results are promising, and exploration of other chemotherapeutic agents to 
possibly achieve even higher response rates could be interesting for the future.  
In conclusion, TM-ILP is an effective treatment option for patients with locally 
advanced cSCC based on this study. Altogether, TM-ILP should be considered as an option in 
locally advanced cSCC patients.  
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Tables and figures 
Table 1. Patients, tumor and treatment characteristics 
 N (%) Median (range) 
Gender   
Male 15 (50)  
Female 15 (50)  
Age   
In  years   71 (36-92) 
Size*   
≤5cm 10 (38)  
>5cm 16 (62)  
Site   
Arm 3 (10)  
Hand or wrist 5 (17)  
Leg 16 (53)  
Ankle or foot 7 (20)  
Number of tumors   
Unifocal 24 (80)  
Multifocal 6 (20)  
Disease stage cSCC at presentation   
Primary  18 (60)  
Recurrent  10 (33)  
Metastatic  2 (7)  
Concurrent metastasis   
None 25 (83)  
Lymph node 3 (10)  
Distant 2 (7)  
Surgical approach   
Axillary 3 (10)  
Brachial 6 (20)  
Femoral 20 (67)  
Iliac 1 (3)  
Doses    
TNF**  (mg)  2 (1-3) 
Melphalan**  (mg)  60 (25-80) 
Hospital stay   
In days   6 (1-72) 
* unknown size (n=4) ** median dose in mg; cSCC = cutaneous squamous cell carcinoma; TM-ILP = 
TNF and melphalan based isolated limb perfusion 
 
Table 2. Patient characteristics per response to ILP  
 CR* (n, %) PR** (n, %) PD*** (n, %) P-value 
Size     1.000
F 
<5cm 6 (43) 2 (50) 2 (40)  
>5cm 8 (57) 2 (50) 3 (60)  
Number of tumors    0.246
F 
Unifocal 13 (81) 5 (83) 3 (60)  
Multifocal 3 (19) 1 (17) 2 (40)  
Disease stage cSCC**** at presentation    0.248
F 
Primary 10 (63) 4 (67) 2 (40)  
Recurrence 2 (12) 1 (17) 1 (20)  
Multiple recurrence 4 (25) 1 (17) 2 (40)  
Location    0.263
F 
Arm 2(13) 0 (0) 1 (20)  
Wrist or hand 2 (13) 2 (33) 0 (0)  
Leg 7 (44) 3 (50) 4 (80)  
Foot or ankle 5 (31) 1 (17) 0 (0)  
*CR=Complete response, **PR=Partial response, ***PD=progressive disease, **** cSCC=cutaneous Squamouscellcarcinoma, F=Fisher exact test 
 
  
 
 
 
 
 
 
  
Table 3. Response, local recurrence and systematic disease 
Type of response*         Patients (n,%) Local progression 
(n, %) 
Months to local 
progression 
(median, range) 
metastatic disease** 
(n,%) 
Months to 
metastatic disease 
(median, range) 
Complete response 16 (59) 4 (25) 9 (9-22) 4*** (25) 0 (0-21) 
Partial response 6 (22) 3 (50) 4 (2-6) 3 (33) 3 (3-9) 
Progressive disease 5 (19) N/A 0 (0-0) 3**** (60) 0 (0-4) 
Overall response 22 (81) 7 (23) 9 (2-22) 10 (32) 3 (0-21) 
*for 3 patients response could not be assessed, ** metastatic disease includes regional and distant metastasis. *** 3 patients already had metastatic 
disease at time of ILP, **** 2 patients already had metastatic disease at time of ILP 
  
 
Figure 1: Course of a complete response of the lower leg 
Pre-ILP TM-ILP Two months after  TM-ILP 
  
 
 
 
 
  
Ongoing response 9 months after TM-ILP 
 
TM-ILP = TNF and melphalan based isolated limb perfusion 
 
  
 
Figure 2: Consort diagram of patients per response group and surgical intervention 
 
 
* in three patients response could not be evaluated 
 
